In a time when pharmaceutical companies no longer have the economic luxury of decades-long development cycles, indication ...

Essentially, what Concr demonstrates is that training their algorithms on smaller, yet more diverse, data can lead to increased accuracy, due to the broader biological variability within that training ...

The analysis found that across all the 339 appraisals carried out for the new medicines, the median gain in quality-adjusted ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for medicines that it says have added around $815 million to US drug spending.

The BBC's probe into Diary of a CEO has followed an increase in emphasis on health topics by Bartlett that, according to the broadcaster, has resulted in a big increase in viewers and subscribers for ...

Editas ended the third quarter with cash reserves of around $256 million, down from $318 million three months earlier. It said at the time that was enough to fund operations to the middle of 2026, but ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

While 2025 remains an unknown quantity, it’s clear that fundraisers and investors see the value in visiting London in ...

Private equity group Carlyle has joined forces with other investors on a €900 million-plus recapitalisation of UK drugmaker ...

Overall, DoE is a valuable approach to improving the quality and efficacy of the final product, streamlining the process, and reducing redundancy — and, consequently, waste. Therefore, it is important ...

As a result of the preliminary STOMP data – which gave the chances of a positive outcome from the study at less than 1% – the ...